NCT02470897 · OUTCOME
Number of Participants Experiencing GI Late Toxicity
Stereotactic Body Radiation Therapy With Boost Using Urethral-Sparing Intensity-Modulated Radiation Therapy Planning in Treating Patients With Prostate Cancer · Source last updated 2026-10-13
Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.
- Measure
- COUNT_OF_PARTICIPANTS
- Unit
- Participants
- Interval / dispersion
- Not reported
- Time frame
- Every 6 months up to 6 years
What was measured
Evaluation of delivering SBRT to the prostate using non-uniform dosing. The investigators will evaluate the potential for any added grade 3 rectal toxicity with the use of a simultaneous integrated boost (Arm A). A late adverse event will be defined as an adverse event occurring more than 90 days from the completion of radiation therapy (RT).
Analysis population: The study was amended from 5 year to 3 year follow up, some participants were on study longer, others were lost to follow up.
Groups in this outcome
Grade 2 Toxicities: Arm A
Incidence of moderate GI toxicities greater than 90 days from completing RT.
Grade 2 Toxicities: Arm B
Incidence of moderate GI toxicities greater than 90 days from completing RT.
Grade 3 Toxicities: Arm A
Incidence of severe GI toxicities greater than 90 days from completing RT.
Grade 3 Toxicities: Arm B
Incidence of severe GI toxicities greater than 90 days from completing RT.
Group identifiers and denominators belong to this outcome only. They may differ in another outcome or in safety reporting.
Analysis denominator · Participants
| Group | Source count |
|---|
| Grade 2 Toxicities: Arm A | 100 |
|---|
| Grade 2 Toxicities: Arm B | 15 |
|---|
| Grade 3 Toxicities: Arm A | 100 |
|---|
| Grade 3 Toxicities: Arm B | 15 |
|---|
Reported measurements
6 months
Analysis denominator · Participants
| Group | Source count |
|---|
| Grade 2 Toxicities: Arm A | 98 |
|---|
| Grade 2 Toxicities: Arm B | 15 |
|---|
| Grade 3 Toxicities: Arm A | 98 |
|---|
| Grade 3 Toxicities: Arm B | 15 |
|---|
Values in Participants · Interval/dispersion: Not reported| Group | Value | Spread | Lower | Upper | Comment |
|---|
| Grade 2 Toxicities: Arm A | 1 | Not reported | Not reported | Not reported | Not reported |
|---|
| Grade 2 Toxicities: Arm B | 0 | Not reported | Not reported | Not reported | Not reported |
|---|
| Grade 3 Toxicities: Arm A | 0 | Not reported | Not reported | Not reported | Not reported |
|---|
| Grade 3 Toxicities: Arm B | 0 | Not reported | Not reported | Not reported | Not reported |
|---|
12 months
Analysis denominator · Participants
| Group | Source count |
|---|
| Grade 2 Toxicities: Arm A | 97 |
|---|
| Grade 2 Toxicities: Arm B | 15 |
|---|
| Grade 3 Toxicities: Arm A | 97 |
|---|
| Grade 3 Toxicities: Arm B | 15 |
|---|
Values in Participants · Interval/dispersion: Not reported| Group | Value | Spread | Lower | Upper | Comment |
|---|
| Grade 2 Toxicities: Arm A | 0 | Not reported | Not reported | Not reported | Not reported |
|---|
| Grade 2 Toxicities: Arm B | 0 | Not reported | Not reported | Not reported | Not reported |
|---|
| Grade 3 Toxicities: Arm A | 0 | Not reported | Not reported | Not reported | Not reported |
|---|
| Grade 3 Toxicities: Arm B | 0 | Not reported | Not reported | Not reported | Not reported |
|---|
18 months
Analysis denominator · Participants
| Group | Source count |
|---|
| Grade 2 Toxicities: Arm A | 96 |
|---|
| Grade 2 Toxicities: Arm B | 12 |
|---|
| Grade 3 Toxicities: Arm A | 96 |
|---|
| Grade 3 Toxicities: Arm B | 12 |
|---|
Values in Participants · Interval/dispersion: Not reported| Group | Value | Spread | Lower | Upper | Comment |
|---|
| Grade 2 Toxicities: Arm A | 2 | Not reported | Not reported | Not reported | Not reported |
|---|
| Grade 2 Toxicities: Arm B | 0 | Not reported | Not reported | Not reported | Not reported |
|---|
| Grade 3 Toxicities: Arm A | 0 | Not reported | Not reported | Not reported | Not reported |
|---|
| Grade 3 Toxicities: Arm B | 0 | Not reported | Not reported | Not reported | Not reported |
|---|
24 months
Analysis denominator · Participants
| Group | Source count |
|---|
| Grade 2 Toxicities: Arm A | 95 |
|---|
| Grade 2 Toxicities: Arm B | 11 |
|---|
| Grade 3 Toxicities: Arm A | 95 |
|---|
| Grade 3 Toxicities: Arm B | 11 |
|---|
Values in Participants · Interval/dispersion: Not reported| Group | Value | Spread | Lower | Upper | Comment |
|---|
| Grade 2 Toxicities: Arm A | 1 | Not reported | Not reported | Not reported | Not reported |
|---|
| Grade 2 Toxicities: Arm B | 0 | Not reported | Not reported | Not reported | Not reported |
|---|
| Grade 3 Toxicities: Arm A | 0 | Not reported | Not reported | Not reported | Not reported |
|---|
| Grade 3 Toxicities: Arm B | 0 | Not reported | Not reported | Not reported | Not reported |
|---|
30 months
Analysis denominator · Participants
| Group | Source count |
|---|
| Grade 2 Toxicities: Arm A | 95 |
|---|
| Grade 2 Toxicities: Arm B | 11 |
|---|
| Grade 3 Toxicities: Arm A | 95 |
|---|
| Grade 3 Toxicities: Arm B | 11 |
|---|
Values in Participants · Interval/dispersion: Not reported| Group | Value | Spread | Lower | Upper | Comment |
|---|
| Grade 2 Toxicities: Arm A | 0 | Not reported | Not reported | Not reported | Not reported |
|---|
| Grade 2 Toxicities: Arm B | 0 | Not reported | Not reported | Not reported | Not reported |
|---|
| Grade 3 Toxicities: Arm A | 0 | Not reported | Not reported | Not reported | Not reported |
|---|
| Grade 3 Toxicities: Arm B | 0 | Not reported | Not reported | Not reported | Not reported |
|---|
36 months
Analysis denominator · Participants
| Group | Source count |
|---|
| Grade 2 Toxicities: Arm A | 92 |
|---|
| Grade 2 Toxicities: Arm B | 11 |
|---|
| Grade 3 Toxicities: Arm A | 92 |
|---|
| Grade 3 Toxicities: Arm B | 11 |
|---|
Values in Participants · Interval/dispersion: Not reported| Group | Value | Spread | Lower | Upper | Comment |
|---|
| Grade 2 Toxicities: Arm A | 1 | Not reported | Not reported | Not reported | Not reported |
|---|
| Grade 2 Toxicities: Arm B | 0 | Not reported | Not reported | Not reported | Not reported |
|---|
| Grade 3 Toxicities: Arm A | 0 | Not reported | Not reported | Not reported | Not reported |
|---|
| Grade 3 Toxicities: Arm B | 0 | Not reported | Not reported | Not reported | Not reported |
|---|
42 months
Analysis denominator · Participants
| Group | Source count |
|---|
| Grade 2 Toxicities: Arm A | 63 |
|---|
| Grade 2 Toxicities: Arm B | 7 |
|---|
| Grade 3 Toxicities: Arm A | 63 |
|---|
| Grade 3 Toxicities: Arm B | 7 |
|---|
Values in Participants · Interval/dispersion: Not reported| Group | Value | Spread | Lower | Upper | Comment |
|---|
| Grade 2 Toxicities: Arm A | 1 | Not reported | Not reported | Not reported | Not reported |
|---|
| Grade 2 Toxicities: Arm B | 0 | Not reported | Not reported | Not reported | Not reported |
|---|
| Grade 3 Toxicities: Arm A | 0 | Not reported | Not reported | Not reported | Not reported |
|---|
| Grade 3 Toxicities: Arm B | 0 | Not reported | Not reported | Not reported | Not reported |
|---|
48 months
Analysis denominator · Participants
| Group | Source count |
|---|
| Grade 2 Toxicities: Arm A | 55 |
|---|
| Grade 2 Toxicities: Arm B | 8 |
|---|
| Grade 3 Toxicities: Arm A | 55 |
|---|
| Grade 3 Toxicities: Arm B | 8 |
|---|
Values in Participants · Interval/dispersion: Not reported| Group | Value | Spread | Lower | Upper | Comment |
|---|
| Grade 2 Toxicities: Arm A | 1 | Not reported | Not reported | Not reported | Not reported |
|---|
| Grade 2 Toxicities: Arm B | 0 | Not reported | Not reported | Not reported | Not reported |
|---|
| Grade 3 Toxicities: Arm A | 0 | Not reported | Not reported | Not reported | Not reported |
|---|
| Grade 3 Toxicities: Arm B | 0 | Not reported | Not reported | Not reported | Not reported |
|---|
54 months
Analysis denominator · Participants
| Group | Source count |
|---|
| Grade 2 Toxicities: Arm A | 47 |
|---|
| Grade 2 Toxicities: Arm B | 7 |
|---|
| Grade 3 Toxicities: Arm A | 47 |
|---|
| Grade 3 Toxicities: Arm B | 7 |
|---|
Values in Participants · Interval/dispersion: Not reported| Group | Value | Spread | Lower | Upper | Comment |
|---|
| Grade 2 Toxicities: Arm A | 0 | Not reported | Not reported | Not reported | Not reported |
|---|
| Grade 2 Toxicities: Arm B | 0 | Not reported | Not reported | Not reported | Not reported |
|---|
| Grade 3 Toxicities: Arm A | 0 | Not reported | Not reported | Not reported | Not reported |
|---|
| Grade 3 Toxicities: Arm B | 0 | Not reported | Not reported | Not reported | Not reported |
|---|
60 months
Analysis denominator · Participants
| Group | Source count |
|---|
| Grade 2 Toxicities: Arm A | 37 |
|---|
| Grade 2 Toxicities: Arm B | 7 |
|---|
| Grade 3 Toxicities: Arm A | 37 |
|---|
| Grade 3 Toxicities: Arm B | 7 |
|---|
Values in Participants · Interval/dispersion: Not reported| Group | Value | Spread | Lower | Upper | Comment |
|---|
| Grade 2 Toxicities: Arm A | 0 | Not reported | Not reported | Not reported | Not reported |
|---|
| Grade 2 Toxicities: Arm B | 0 | Not reported | Not reported | Not reported | Not reported |
|---|
| Grade 3 Toxicities: Arm A | 0 | Not reported | Not reported | Not reported | Not reported |
|---|
| Grade 3 Toxicities: Arm B | 0 | Not reported | Not reported | Not reported | Not reported |
|---|
72 months
Analysis denominator · Participants
| Group | Source count |
|---|
| Grade 2 Toxicities: Arm A | 16 |
|---|
| Grade 2 Toxicities: Arm B | 5 |
|---|
| Grade 3 Toxicities: Arm A | 16 |
|---|
| Grade 3 Toxicities: Arm B | 5 |
|---|
Values in Participants · Interval/dispersion: Not reported| Group | Value | Spread | Lower | Upper | Comment |
|---|
| Grade 2 Toxicities: Arm A | 0 | Not reported | Not reported | Not reported | Not reported |
|---|
| Grade 2 Toxicities: Arm B | 0 | Not reported | Not reported | Not reported | Not reported |
|---|
| Grade 3 Toxicities: Arm A | 0 | Not reported | Not reported | Not reported | Not reported |
|---|
| Grade 3 Toxicities: Arm B | 0 | Not reported | Not reported | Not reported | Not reported |
|---|
Complete source fields
- classes
- categories
- measurements
- group Id
- OG000
- value
- 1
- group Id
- OG001
- value
- 0
- group Id
- OG002
- value
- 0
- group Id
- OG003
- value
- 0
- denoms
- counts
- group Id
- OG000
- value
- 98
- group Id
- OG001
- value
- 15
- group Id
- OG002
- value
- 98
- group Id
- OG003
- value
- 15
- units
- Participants
- title
- 6 months
- categories
- measurements
- group Id
- OG000
- value
- 0
- group Id
- OG001
- value
- 0
- group Id
- OG002
- value
- 0
- group Id
- OG003
- value
- 0
- denoms
- counts
- group Id
- OG000
- value
- 97
- group Id
- OG001
- value
- 15
- group Id
- OG002
- value
- 97
- group Id
- OG003
- value
- 15
- units
- Participants
- title
- 12 months
- categories
- measurements
- group Id
- OG000
- value
- 2
- group Id
- OG001
- value
- 0
- group Id
- OG002
- value
- 0
- group Id
- OG003
- value
- 0
- denoms
- counts
- group Id
- OG000
- value
- 96
- group Id
- OG001
- value
- 12
- group Id
- OG002
- value
- 96
- group Id
- OG003
- value
- 12
- units
- Participants
- title
- 18 months
- categories
- measurements
- group Id
- OG000
- value
- 1
- group Id
- OG001
- value
- 0
- group Id
- OG002
- value
- 0
- group Id
- OG003
- value
- 0
- denoms
- counts
- group Id
- OG000
- value
- 95
- group Id
- OG001
- value
- 11
- group Id
- OG002
- value
- 95
- group Id
- OG003
- value
- 11
- units
- Participants
- title
- 24 months
- categories
- measurements
- group Id
- OG000
- value
- 0
- group Id
- OG001
- value
- 0
- group Id
- OG002
- value
- 0
- group Id
- OG003
- value
- 0
- denoms
- counts
- group Id
- OG000
- value
- 95
- group Id
- OG001
- value
- 11
- group Id
- OG002
- value
- 95
- group Id
- OG003
- value
- 11
- units
- Participants
- title
- 30 months
- categories
- measurements
- group Id
- OG000
- value
- 1
- group Id
- OG001
- value
- 0
- group Id
- OG002
- value
- 0
- group Id
- OG003
- value
- 0
- denoms
- counts
- group Id
- OG000
- value
- 92
- group Id
- OG001
- value
- 11
- group Id
- OG002
- value
- 92
- group Id
- OG003
- value
- 11
- units
- Participants
- title
- 36 months
- categories
- measurements
- group Id
- OG000
- value
- 1
- group Id
- OG001
- value
- 0
- group Id
- OG002
- value
- 0
- group Id
- OG003
- value
- 0
- denoms
- counts
- group Id
- OG000
- value
- 63
- group Id
- OG001
- value
- 7
- group Id
- OG002
- value
- 63
- group Id
- OG003
- value
- 7
- units
- Participants
- title
- 42 months
- categories
- measurements
- group Id
- OG000
- value
- 1
- group Id
- OG001
- value
- 0
- group Id
- OG002
- value
- 0
- group Id
- OG003
- value
- 0
- denoms
- counts
- group Id
- OG000
- value
- 55
- group Id
- OG001
- value
- 8
- group Id
- OG002
- value
- 55
- group Id
- OG003
- value
- 8
- units
- Participants
- title
- 48 months
- categories
- measurements
- group Id
- OG000
- value
- 0
- group Id
- OG001
- value
- 0
- group Id
- OG002
- value
- 0
- group Id
- OG003
- value
- 0
- denoms
- counts
- group Id
- OG000
- value
- 47
- group Id
- OG001
- value
- 7
- group Id
- OG002
- value
- 47
- group Id
- OG003
- value
- 7
- units
- Participants
- title
- 54 months
- categories
- measurements
- group Id
- OG000
- value
- 0
- group Id
- OG001
- value
- 0
- group Id
- OG002
- value
- 0
- group Id
- OG003
- value
- 0
- denoms
- counts
- group Id
- OG000
- value
- 37
- group Id
- OG001
- value
- 7
- group Id
- OG002
- value
- 37
- group Id
- OG003
- value
- 7
- units
- Participants
- title
- 60 months
- categories
- measurements
- group Id
- OG000
- value
- 0
- group Id
- OG001
- value
- 0
- group Id
- OG002
- value
- 0
- group Id
- OG003
- value
- 0
- denoms
- counts
- group Id
- OG000
- value
- 16
- group Id
- OG001
- value
- 5
- group Id
- OG002
- value
- 16
- group Id
- OG003
- value
- 5
- units
- Participants
- title
- 72 months
- denoms
- counts
- group Id
- OG000
- value
- 100
- group Id
- OG001
- value
- 15
- group Id
- OG002
- value
- 100
- group Id
- OG003
- value
- 15
- units
- Participants
- description
- Evaluation of delivering SBRT to the prostate using non-uniform dosing. The investigators will evaluate the potential for any added grade 3 rectal toxicity with the use of a simultaneous integrated boost (Arm A). A late adverse event will be defined as an adverse event occurring more than 90 days from the completion of radiation therapy (RT).
- groups
- description
- Incidence of moderate GI toxicities greater than 90 days from completing RT.
- id
- OG000
- title
- Grade 2 Toxicities: Arm A
- description
- Incidence of moderate GI toxicities greater than 90 days from completing RT.
- id
- OG001
- title
- Grade 2 Toxicities: Arm B
- description
- Incidence of severe GI toxicities greater than 90 days from completing RT.
- id
- OG002
- title
- Grade 3 Toxicities: Arm A
- description
- Incidence of severe GI toxicities greater than 90 days from completing RT.
- id
- OG003
- title
- Grade 3 Toxicities: Arm B
- param Type
- COUNT_OF_PARTICIPANTS
- population Description
- The study was amended from 5 year to 3 year follow up, some participants were on study longer, others were lost to follow up.
- reporting Status
- POSTED
- time Frame
- Every 6 months up to 6 years
- title
- Number of Participants Experiencing GI Late Toxicity
- type
- PRIMARY
- unit Of Measure
- Participants
Download exact source JSON → · Snapshot ctgov-results-d643ffaf417bcef6d45eb5e0
Preserved source evidence · Not medical advice